Want to see SE:ACARIX full AI Analyst Report?
ACARIX Stock Chart & Stats
kr0.28
>-kr0.01(-3.04%)
At close: 4:00 PM EST
kr0.28
>-kr0.01(-3.04%)
Day’s Range― - ―
52-Week Rangekr0.22 - kr0.35
Previous CloseN/A
Volume265.37K
Average Volume (3M)1.57M
Market Cap
kr262.86M
Enterprise Valuekr279.54
Total Cash (Recent Filing)kr28.88M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta-0.16
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding1,123,320,200
10 Day Avg. Volume1,780,482
30 Day Avg. Volume1,572,056
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)7.91
Price to Sales (P/S)41.02
P/FCF Ratio-6.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.1
Revenue Forecast (FY)kr19.10M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthImproving revenue shows continued commercial traction for Acarix’s cardiovascular diagnostic offering. Sustained growth can expand the installed base and improve operating leverage if adoption continues across healthcare providers.
Gross Margin ImprovementThe substantial margin improvement indicates better unit economics and a potentially more attractive product mix. If maintained, stronger gross profit generation could help fund commercialization and reduce the scale of future losses.
Debt-Free Balance SheetA debt-free capital structure limits refinancing obligations and interest-rate exposure. This gives Acarix greater financial flexibility than a similarly loss-making company with significant leverage, although it does not remove funding needs.
Bears Say
Deep Operating LossesProfitability remains far below breakeven, showing that the current revenue base does not cover the company’s cost structure. Persistent operating losses could limit reinvestment capacity and require additional capital before scale benefits emerge.
Persistent Cash BurnNegative operating and free cash flow mean the business is not yet self-funding. Even though cash burn improved versus 2025, continued dependence on external financing can constrain strategy and create execution risk over the medium term.
Eroding EquityOngoing losses are consuming the company’s equity base, weakening financial resilience despite zero debt. Unless operating performance improves materially, further capital raising or dilution may be needed to sustain operations and commercialization.
Acarix AB News
ACARIX FAQ
What was Acarix AB’s price range in the past 12 months?
Acarix AB lowest stock price was kr0.22 and its highest was kr0.35 in the past 12 months.
What is Acarix AB’s market cap?
Acarix AB’s market cap is kr262.86M.
When is Acarix AB’s upcoming earnings report date?
Acarix AB’s upcoming earnings report date is Nov 05, 2026 which is in 74 days.
How were Acarix AB’s earnings last quarter?
Acarix AB released its earnings results on Aug 13, 2026. The company reported -kr0.008 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Acarix AB overvalued?
According to Wall Street analysts Acarix AB’s price is currently Overvalued.
Does Acarix AB pay dividends?
Acarix AB does not currently pay dividends.
What is Acarix AB’s EPS estimate?
Acarix AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Acarix AB have?
Acarix AB has 1,123,320,200 shares outstanding.
What happened to Acarix AB’s price movement after its last earnings report?
Acarix AB reported an EPS of -kr0.008 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Acarix AB?
Currently, no hedge funds are holding shares in SE:ACARIX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Acarix AB
Acarix AB (publ) is a medical technology company that develops and introduces diagnostic solutions for cardiovascular conditions to markets including Germany, Sweden, the Middle East, Switzerland, Austria, and globally. Their key product is the CADScor System, an exceptionally sensitive, non-invasive analytical device designed for the detection of coronary artery disease. Founded in 2009, Acarix AB (publ) maintains its headquarters in Malmö, Sweden.
Technical Analysis
Senzime AB
―
Bactiguard Holding AB
―
Sectra AB Class B
―
Scandinavian Real Heart AB
―
Mentice AB
―